Shares of Syndax Pharmaceuticals (SNDX) have gained 7.2% over the past four weeks to close the last trading session at $21.13, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.31 indicates a potential upside of 67.1%.The mean estimate comprises 13 short-term price targets with a standard deviation of $6.28. While the lowest estimate of $23 indicates an 8.9% increase from the ...